Every 424B that Erasca, Inc. (ERAS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ERAS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERAS filings page.
Erasca, Inc. is offering 31,428,572 shares of its common stock at $17.50 per share, for gross proceeds of $550,000,010, with an underwriters’ 30‑day option for up to 4,714,285 additional shares. Estimated net proceeds are about $516.0 million, to fund RAS/MAPK‑focused research and development, other development programs, working capital and general corporate purposes, and potentially in‑licensing or acquisitions. Based on 310,806,888 shares outstanding as of March 31 2026, the company calculates an as‑adjusted net tangible book value of $2.66 per share, implying $14.84 per‑share dilution to new investors. A separate at‑the‑market program still has $200 million of capacity.
Erasca is a clinical‑stage precision oncology company targeting RAS/MAPK pathway‑driven cancers, with clinical programs ERAS‑0015 and ERAS‑4001 and discovery asset ERAS‑12. Updated AURORAS‑1 Phase 1 data for ERAS‑0015 in RAS‑mutant solid tumors show treatment‑related rash in 72% of 72 patients, diarrhea in 32%, stomatitis in 19%, nausea in 14%, and no treatment‑related adverse events leading to dose discontinuations.
Erasca, Inc. is conducting a primary offering of $500,000,000 of common stock under its shelf registration, with underwriters holding a 30‑day option to buy up to an additional $75,000,000. Its common stock trades on the Nasdaq Global Select Market under the symbol “ERAS,” last reported at $18.53 on July 10, 2026.
Shares outstanding were 310,806,888 as of March 31, 2026; this is a baseline figure, not the amount being offered, and excludes any shares from this transaction or up to $200 million available under an at‑the‑market Sales Agreement. The company is a clinical‑stage precision oncology developer targeting RAS/MAPK‑driven cancers, with clinical programs ERAS‑0015 (pan‑RAS molecular glue) and ERAS‑4001 (pan‑KRAS inhibitor) plus discovery program ERAS‑12. Net proceeds, together with existing cash, will fund research and development, working capital, general corporate purposes and potential in‑licensing or acquisitions.
Erasca highlights that new investors will experience immediate and substantial dilution relative to net tangible book value of $393.5 million, or $1.27 per share, as of March 31, 2026. Updated preliminary AURORAS‑1 Phase 1 data for ERAS‑0015 in 72 patients with RAS‑mutant NSCLC and PDAC treated at 16–32 mg showed treatment‑related rash in 72% and diarrhea in 32% of patients.
Erasca, Inc. is conducting a primary offering of 22,500,000 shares of its common stock at $10.00 per share, for gross proceeds of $225.0 million and estimated net proceeds of about $211.0 million after underwriting fees and expenses. The company has granted underwriters a 30‑day option to purchase up to 3,375,000 additional shares.
Erasca plans to use the net proceeds, together with its existing cash, cash equivalents and marketable securities, to fund research and development of its oncology product candidates and other programs, and for working capital and general corporate purposes, with potential in-licensing or acquisitions as opportunities arise. As of September 30, 2025, Erasca had 283,711,805 shares outstanding, and investors in this offering will experience immediate dilution, with an estimated $8.18 per-share dilution based on the net tangible book value at that date.
Erasca, Inc. is conducting a primary offering of $150,000,000 of its common stock under a shelf registration, with underwriters holding an option to buy up to an additional $22,500,000 of shares from the company.
Erasca is a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers. Its pipeline includes three clinical-stage programs—ERAS-0015 (pan-RAS molecular glue), ERAS-4001 (pan-KRAS inhibitor) and naporafenib (pan-RAF inhibitor)—plus ERAS-12, an EGFR D2/D3 biparatopic antibody in discovery.
As of September 30, 2025, Erasca had 283,711,805 shares of common stock outstanding and net tangible book value of approximately $347.9 million, or $1.23 per share. A preliminary update indicates cash, cash equivalents and marketable securities of approximately $341.8 million as of December 31, 2025. The company plans to use offering proceeds, together with existing cash, to fund research and development, other programs, working capital and general corporate purposes, and may also in-license or acquire complementary assets. The company warns of immediate and substantial dilution to new investors and highlights significant risks associated with this offering.